South San Francisco, CA – Veracyte Inc. has announced the appointment of Kevin Haas as Chief Development and Technology Officer. About Veracyte Inc.: Veracyte Inc. is a leader in cancer genomic testing and molecular diagnostics, developing and commercializing innovative tests that transform cancer care for hundreds of thousands of patients while advancing scientific understanding. The company helps clinicians provide informed answers and personalized treatment plans through collaborative research and comprehensive test data, supporting advances in precision cancer care. Key products include the Afirma Genomic Sequencing Classifier and Xpression Atlas for thyroid cancer risk assessment, Percepta Bronchial Genomic Classifier to improve lung cancer diagnosis, Envisia Genomic Classifier for idiopathic pulmonary fibrosis, and Prosigna Breast Cancer Prognostic Gene Signature Assay to guide early-stage breast cancer management. Operating as a public company headquartered in South San Francisco, California, Veracyte generates revenue from testing services, product sales like Prosigna kits, and biopharmaceutical partnerships, with 2024 net revenue reaching $445.8 million.

For more information on Veracyte Inc. please visit: https://www.veracyte.com/

Veracyte Inc.
6000 Shoreline Court, Suite 300
South San Francisco, CA 94080
Phone: 650-243-6300
LinkedIn Page: https://www.linkedin.com/company/veracyte/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved